| Brand name | ActiTide-AH3(Liquefied 1000) |
| CAS No. | 616204-22-9; 56-81-5; 107-88-0; 7732-18-5; 99-93-4; 6920-22-5 |
| INCI Name | Acetyl Hexapeptide-8; Glycerin; Butylene Glycol; Water; Hydroxyacetophenone; 1,2-Hexanediol |
| Application | Lotion, Serums, Mask, Facial cleanser |
| Package | 1kg/bottle |
| Appearance | Clear transparent liquid with characteristic odor |
| Solubility | Water soluble |
| Function | Peptide series |
| Shelf life | 2 years |
| Storage | Store the container tightly closed in a dry, cool and well-ventilated place. |
| Dosage | 3.0-10.0% |
Research into fundamental anti-wrinkle mechanisms led to the discovery of ActiTide-AH3, an innovative hexapeptide developed through a scientific approach from rational design to GMP production, with positive results.
ActiTide-AH3 delivers wrinkle-reducing efficacy comparable to Botulinum Toxin Type A, while avoiding injection risks and offering greater cost-effectiveness.
Cosmetic Benefits:
ActiTide-AH3 reduces wrinkle depth caused by facial muscle contraction, with pronounced effects on forehead and periocular wrinkles.
Mechanism of Action:
Muscle contraction occurs upon neurotransmitter release from synaptic vesicles. The SNARE complex – a ternary assembly of VAMP, Syntaxin, and SNAP-25 proteins – is essential for vesicle docking and neurotransmitter exocytosis (A. Ferrer Montiel et al., JBC 1997, 272:2634-2638). This complex acts as a cellular hook, capturing vesicles and driving membrane fusion.
As a structural mimetic of the SNAP-25 N-terminus, ActiTide-AH3 competes with SNAP-25 for incorporation into the SNARE complex, modulating its assembly. Destabilization of the SNARE complex impairs vesicle docking and subsequent neurotransmitter release, leading to reduced muscle contraction and prevention of wrinkle and fine line formation.
ActiTide-AH3 is a safer, more economical, and gentler alternative to Botulinum Toxin Type A. It topically targets the same wrinkle-formation pathway but operates via a distinct mechanism.
